| Literature DB >> 1906375 |
R E Botti1, J Triscari, H Y Pan, J Zayat.
Abstract
The capability of pravastatin and lovastatin, HMG-CoA reductase inhibitors likely to be taken chronically for hypercholesterolemia, to cross the blood-brain barrier was investigated in normal male volunteers. Lovastatin, which is lipophilic, was detected in cerebrospinal fluid (CSF) at concentrations that may have a pharmacologic effect. Pravastatin, which is hydrophilic, was not detected in CSF. It is concluded that pravastatin may have less potential for causing CNS-related side effects than lovastatin.Entities:
Mesh:
Substances:
Year: 1991 PMID: 1906375 DOI: 10.1097/00002826-199106000-00010
Source DB: PubMed Journal: Clin Neuropharmacol ISSN: 0362-5664 Impact factor: 1.592